Understanding how MUC5B contributes to lung fibrosis
Endoplasmic reticulum stress in MUC5B-driven lung fibrosis
This study is looking at how a protein called MUC5B affects lung health in people with idiopathic pulmonary fibrosis (IPF) by causing stress in lung cells, and it hopes to find new ways to help treat this condition.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10815873 on NIH RePORTER |
What this research studies
This research investigates the role of MUC5B, a protein linked to lung fibrosis, particularly in patients with idiopathic pulmonary fibrosis (IPF). The team aims to uncover how increased levels of MUC5B lead to damage in lung epithelial cells and contribute to the development of fibrosis. They will explore the mechanisms behind this process, focusing on the relationship between MUC5B expression and endoplasmic reticulum (ER) stress in lung cells. By using both human samples and animal models, the research seeks to provide insights into potential therapeutic targets for treating lung fibrosis.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with idiopathic pulmonary fibrosis, particularly those with the MUC5B promoter variant.
Not a fit: Patients without a diagnosis of idiopathic pulmonary fibrosis or those not expressing the MUC5B promoter variant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or reduce lung fibrosis in patients with IPF.
How similar studies have performed: Previous research has shown promising results in understanding the role of MUC5B in lung fibrosis, suggesting that this approach could yield valuable insights.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Schwartz, David Albert — University of Colorado Denver
- Study coordinator: Schwartz, David Albert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.